Market Place
Sourcing Support
FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments
This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s
Covid-19 HCQ update: Studies in France, Brazil, China raise more questions on its efficacy, safety
Last month, we had carried an article ‘Hydroxychloroquine: Hype versus reality’ that
hi
Chinese industrial activity revival at 98.6 percent, officials assure of API supplies
While the world feels the heat of the Covid-19 pandemic with the global pharmaceutical supply chain
Hydroxychloroquine: Hype versus reality
The
President of United States Donald Trump’s
tweet
late last week has swung the pharmaceut
COVID-19: India restricts drug exports amid rising prices of essential bulk drugs; FDA announces first drug shortage
Now that it has been
established that the novel coronavirus is going to globally impact the drug
s
Mid 2018 – Recap of Warning Letters, Import Alerts and Non-Compliances
In our mid-2018 compliance review, we look at inspection challenges
faced by companies across the w
Analyzing over US$ 90 billion of Medicare Prescription Drug (Part D) Spending in 2016
This week, PharmaCompass
reviews the recently released data on prescription drugs paid for under th
Drug costs and prescription trends in the United States: Analyzing Medicare’s $121 billion spend
In less than three weeks, Donald Trump will assume office as the
President of the United States. He
China shuts plants of major antibiotic producers to fight pollution; more troubles for Teva
This week, Phispers has lots on generics. While the global leader Teva has more troubles at hand, ge
Sandoz, Mylan, Hetero, Lupin face the heat due to data manipulation at Semler
In April 2016, the US Food and Drug Administration (FDA) came
down heavily on Semler Research Center
